Imugene Limited (ASX: IMU)
Australia
· Delayed Price · Currency is AUD 0.0370
-0.0030 (-7.50%)
Nov 21, 2024, 4:10 PM AEST
Imugene Revenue
In the fiscal year ending June 30, 2024, Imugene had annual revenue of 4.97M AUD, down -57.80%. Imugene had revenue of -3.10M in the half year ending June 30, 2024, a decrease of -140.63%.
Revenue
4.97M
Revenue Growth
-57.80%
P/S Ratio
52.78
Revenue / Employee
994.01K
Employees
5
Market Cap
275.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
| Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
| Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
| Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
| Jun 30, 2020 | 4.13M | 6.56K | 0.16% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 22.18B |
| ResMed Inc. | 6.93B |
| Pro Medicus Limited | 161.50M |
| Fisher & Paykel Healthcare Corporation Limited | 1.60B |
| Cochlear Limited | 2.24B |
| Sonic Healthcare Limited | 8.97B |
| Ramsay Health Care Limited | 16.66B |
| Telix Pharmaceuticals Limited | 645.68M |
Imugene News
- 2 months ago - Imugene Ltd Azer-cel Trial Update Transcript - GuruFocus
- 7 months ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 8 months ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 9 months ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 10 months ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire
- 1 year ago - NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments - PRNewsWire
- 2 years ago - City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors - Business Wire
- 2 years ago - Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer - GlobeNewsWire